Assembly Biosciences, Inc. (NASDAQ:ASMB – Get Free Report) was the target of a significant drop in short interest in April. As of April 15th, there was short interest totalling 30,600 shares, a drop of 28.2% from the March 31st total of 42,600 shares. Based on an average daily trading volume, of 27,700 shares, the days-to-cover ratio is currently 1.1 days. Approximately 0.8% of the company’s stock are short sold.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on the stock. HC Wainwright reaffirmed a “neutral” rating on shares of Assembly Biosciences in a research report on Monday, April 1st. StockNews.com raised shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Friday, April 5th.
Read Our Latest Report on Assembly Biosciences
Institutional Inflows and Outflows
Assembly Biosciences Trading Down 5.3 %
NASDAQ:ASMB traded down $0.71 on Friday, hitting $12.65. The company’s stock had a trading volume of 29,550 shares, compared to its average volume of 17,185. Assembly Biosciences has a one year low of $7.69 and a one year high of $20.04. The firm has a market capitalization of $69.32 million, a P/E ratio of -0.74 and a beta of 0.57. The stock has a fifty day moving average of $13.07 and a two-hundred day moving average of $11.05.
About Assembly Biosciences
Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.
See Also
- Five stocks we like better than Assembly Biosciences
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- MarketBeat Week in Review – 4/22 – 4/26
- Which Wall Street Analysts are the Most Accurate?
- 3 Stocks Leading the U.S. Agriculture Comeback
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.